Trisha Almazi

Dr Trisha Almazi received her PhD in cancer biology in 2014 from the University of Sydney, Australia and joined the Respiratory Technology group in 2021. Trisha currently has a 50:50 appointment as a research academic at the Woolcock Institute of Medical Research (WIMR) and lead scientist at Ab Initio Pharma. She has a research interest in translational research, drug delivery, drug characterisation, chemical proteomics, cancer, and chronic obstructive respiratory disease. Her expertise includes mass spectrometry, biological characterisation of inhalation therapies, and cell/cancer biology. Trisha is an active member of the ECR committee and Chair of the Work Health and Safety committee at WIMR. She has presented her work at several national and international conferences and her work has recently been translated into a marketed product.